ArticleFrontiers in nutrition2026
An activity labelled molecular networking strategy-assisted discovery of antiplatelet aggregation-active components from
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: This study identified steroidal saponins using a targeted molecular networking (TMN) approach and explored the mechanism of antiplatelet aggregation. Results: ACGD samples (1 mg/mL) extracted using different solvents (water, 30% methanol, 50% methanol, 70% methanol, and 100% methanol) all exhibited inhibitory effects on platelet aggregation induced by adenosine diphosphate, arachidonic acid, and collagen. The ACGD fraction extracted with 70% methanol (1 mg/mL) displayed the strongest inhibitory effects. Furthermore, a total of 36 steroidal saponins were visualized based on TMN analysis. These components were identified or tentatively characterized according to their retention behaviors, diagnostic ions, and fragmentation patterns. Among them, laxogenin-related furostanol and spirostanol saponins were the most abundant saponins in ACGD. A total of 15 saponins with antiplatelet aggregation activity, high content levels, different structural types, or authentic standards were selected to perform the network pharmacology analysis. The PI3K/Akt pathway is one of the most important signaling pathways in platelet activation. Moreover, based on CCK-8 assays in MEG-01 cells, compounds T3-12, T3-14, T3-15, T3-16, and T3-17 were non-toxic and did not induce proliferation at 5-20 μM. Moreover, compounds T3-15, T3-16, and T3-17 at 20 μM caused downregulation of the Discussion: The TMN approach, integrated with diagnostic ions, was successfully applied to characterize target steroidal saponins in ACGD. Compounds T3-16 and T3-17 were confirmed to be active components in ACGD in antiplatelet aggregation through the PI3K/Akt pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.